COLL — Collegium Pharmaceutical Share Price
0.000.00%
Last trade - 00:00- $860.81m
- $1.55bn
- $631.45m
- 64
- 82
- 76
- 87
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 3.82 | ||
| PEG Ratio (f) | 0.09 | ||
| EPS Growth (f) | 80.66% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.76 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 4.23 | ||
| Price to Sales | 1.36 | ||
| EV to EBITDA | 4.73 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.74% | ||
| Return on Equity | 32.62% | ||
| Operating Margin | 25.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 310.02 | 276.87 | 463.93 | 566.77 | 631.45 | 742.62 | 771.82 | 16.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +159.54 | n/a | n/a | +39.07 | +178.09 | +5.46 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
Directors
- Michael Heffernan CHM (56)
- Joseph Ciaffoni PRE (50)
- Colleen Tupper CFO (45)
- Shirley Kuhlmann EVP (37)
- Scott Dreyer EVP (48)
- Richard Malamut EVP (61)
- Scott Sudduth EVP
- Gino Santini LED (65)
- Rita Balice-Gordon IND (60)
- Garen Bohlin IND (73)
- John Fallon IND (73)
- John Freund IND (67)
- Gwen Melincoff IND (69)
- Theodore Schroeder IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 1st, 2014
- Public Since
- May 7th, 2015
- No. of Shareholders
- 12
- No. of Employees
- 357
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 32,131,798
- Address
- 100 Technology Center Dr, STOUGHTON, 02072-4710
- Web
- https://www.collegiumpharma.com/
- Phone
- +1 7817133699
- Auditors
- Deloitte & Touche LLP
Upcoming Events for COLL
Q1 2025 Collegium Pharmaceutical Inc Earnings Call
Collegium Pharmaceutical Inc Annual Shareholders Meeting
Collegium Pharmaceutical Inc Annual Shareholders Meeting
Q2 2025 Collegium Pharmaceutical Inc Earnings Release
Similar to COLL
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Collegium Pharmaceutical share price?
As of Today at 20:00 UTC, shares in Collegium Pharmaceutical are trading at $26.79. This share price information is delayed by 15 minutes.
How has the Collegium Pharmaceutical share price performed this year?
Shares in Collegium Pharmaceutical last closed at $26.79 and the price had moved by -25.25% over the past 365 days. In terms of relative price strength the Collegium Pharmaceutical share price has underperformed the S&P500 Index by -31% over the past year.
What are the analyst and broker recommendations for Collegium Pharmaceutical?
The overall consensus recommendation for Collegium Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Collegium Pharmaceutical dividend yield?
Collegium Pharmaceutical does not currently pay a dividend.
Does Collegium Pharmaceutical pay a dividend?
Collegium Pharmaceutical does not currently pay a dividend.
When does Collegium Pharmaceutical next pay dividends?
Collegium Pharmaceutical does not currently pay a dividend.
How do I buy Collegium Pharmaceutical shares?
To buy shares in Collegium Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Collegium Pharmaceutical?
As of the previous close price of $26.79, shares in Collegium Pharmaceutical had a market capitalisation of $860.81m.
Where are Collegium Pharmaceutical shares listed?
Here are the trading details for Collegium Pharmaceutical:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: COLL
What kind of share is Collegium Pharmaceutical?
Based on an overall assessment of its quality, value and momentum Collegium Pharmaceutical is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Collegium Pharmaceutical share price forecast for 2025?
The analyst consensus target price for shares in Collegium Pharmaceutical is $42.80. That is 59.76% above the last closing price of $26.79.
Analysts covering Collegium Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of $6.89 for the next financial year.
Find out moreWhat is the trend in the Collegium Pharmaceutical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Collegium Pharmaceutical. Over the past six months, its share price has underperformed the S&P500 Index by -18.63%.
As of the last closing price of $26.79, shares in Collegium Pharmaceutical were trading -17.93% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Collegium Pharmaceutical PE Ratio?
The Collegium Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 3.82. The shares last closed at $26.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Collegium Pharmaceutical?
Collegium Pharmaceutical's management team is headed by:
- Michael Heffernan - CHM
- Joseph Ciaffoni - PRE
- Colleen Tupper - CFO
- Shirley Kuhlmann - EVP
- Scott Dreyer - EVP
- Richard Malamut - EVP
- Scott Sudduth - EVP
- Gino Santini - LED
- Rita Balice-Gordon - IND
- Garen Bohlin - IND
- John Fallon - IND
- John Freund - IND
- Gwen Melincoff - IND
- Theodore Schroeder - IND